Compare Biogen Inc (BIIB) vs Plug Power Inc (PLUG) Price & Performance

Biogen IncTrade

Plug Power IncTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Plug Power Inc — how do they compare? Biogen Inc trades at $191.9 (market cap $30.86B), while Plug Power Inc trades at $2.3 (market cap $3.03B). The key difference: Biogen Inc is far larger — about 10.2× Plug Power Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.

	BIIB	PLUG
Market Cap	$30.86B	$3.03B
Sector	Health	Industrials
52-Week High	$216.63	$4.14
52-Week Low	$122.68	$1.40
Enterprise Value	$33.14B	$3.81B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

No Aura AI signal available yet.

Plug Power Inc

Plug Power (PLUG) trades at $2.17, down 2.69% with a bearish technical signal. The company shows persistent financial challenges with negative profit margins (-227.13% net income margin) and cash flow issues, though recent asset sales aim to improve liquidity. Revenue grew to $710M in 2025 but remains unprofitable with significant losses. Analyst sentiment is mixed with 44.7% buy ratings and a $2.92 consensus target, while technical indicators show oversold conditions with RSI at 18.61.

The outlook remains challenging with profitability projected for 2028, but execution risks and continued cash burn pose significant hurdles. Near-term catalysts include $80M liquidity from recent asset sales and project milestones, though elevated short interest at 27.4% reflects skepticism. Investors face high volatility amid the company's turnaround efforts in the competitive hydrogen sector.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BIIB

Real-world study shows 83% of early Alzheimer's patients stable or improved on LEQEMBI over 17 monthsPRNewsWire · 22 hours agoBullish Biogen's diranersen shows promising Phase 2 results slowing early Alzheimer's decline and reducing tau protein.GlobeNewsWire · 1 day agoBullish FDA approves LEQEMBI IQLIK, first at-home weekly injection for early Alzheimer's treatmentPRNewsWire · 1 day agoBullish View details →

PLUG

Plug Power sells Texas project and advances New York deal, expects $80M liquidity boost soonGlobeNewsWire · 2 days agoBullish View details →

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

About Plug Power Inc

Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.